Johnson & Johnson Uses AI to Accelerate Drug Discovery by 50%

Johnson & Johnson is using AI to accelerate drug discovery efforts, saying the technology has cut the time needed to generate early-stage drug development leads by half.

The company revealed that AI drug discovery tools are helping researchers quickly scan vast datasets of chemical and biological compounds, narrowing down the most promising candidates far faster than traditional methods.

The shift is already showing results in key areas like oncology and immunology, where early identification of viable drug targets is critical.

While AI is not yet capable of fully developing a drug end-to-end, it is significantly reducing the time spent in the initial discovery phase, which has long been one of the slowest parts of the process.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Beyond discovery, the company is applying AI across clinical trials. Tasks that once took between 700 and 900 hours, such as compiling detailed clinical study reports, can now be completed in around 15 minutes. This change is helping teams move faster while maintaining accuracy and compliance.

AI is also improving manufacturing efficiency. It is being used to determine precise timings and methods for adding solvents and other materials, leading to more consistent production outcomes. In medical technology, the company is leveraging AI to enhance procedures, including faster heart mapping for arrhythmia treatments and improved precision in joint replacement surgeries.

Despite concerns around automation, Johnson & Johnson emphasized that AI is not replacing jobs but reshaping them. Employees are being equipped with new skills to work alongside these tools, making processes more efficient without reducing the workforce.

With drug development often taking over a decade and costing billions, the integration of AI marks a significant step toward faster, more efficient innovation in the pharmaceutical industry.